Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Mycolic acids (MAs) are the characteristic, integral building blocks for the mycomembrane belonging to the insidious bacterial pathogen Mycobacterium tuberculosis (M.tb). These C60-C90 long α-alkyl-β-hydroxylated fatty acids provide protection to the tubercle bacilli against the outside threats, thus allowing its survival, virulence and resistance to the current antibacterial agents. In the post-genomic era, progress has been made towards understanding the crucial enzymatic machineries involved in the biosynthesis of MAs in M.tb. However, gaps still remain in the exact role of the phosphorylation and dephosphorylation of regulatory mechanisms within these systems. To date, a total of 11 serine-threonine protein kinases (STPKs) are found in M.tb. Most enzymes implicated in the MAs synthesis were found to be phosphorylated in vitro and/or in vivo. For instance, phosphorylation of KasA, KasB, mtFabH, InhA, MabA, and FadD32 downregulated their enzymatic activity, while phosphorylation of VirS increased its enzymatic activity. These observations suggest that the kinases and phosphatases system could play a role in M.tb adaptive responses and survival mechanisms in the human host. As the mycobacterial STPKs do not share a high sequence homology to the human's, there have been some early drug discovery efforts towards developing potent and selective inhibitors.
OBJECTIVE: Recent updates to the kinases and phosphatases involved in the regulation of MAs biosynthesis will be presented in this mini-review, including their known small molecule inhibitors.
CONCLUSION: Mycobacterial kinases and phosphatases involved in the MAs regulation may serve as a useful avenue for antitubercular therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - 12(2019), 1 vom: 25., Seite 27-49 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alsayed, Shahinda S R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.06.2019 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1874467211666181025141114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289948673 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289948673 | ||
| 003 | DE-627 | ||
| 005 | 20231225063652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1874467211666181025141114 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0966.xml |
| 035 | |a (DE-627)NLM289948673 | ||
| 035 | |a (NLM)30360731 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alsayed, Shahinda S R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2019 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Mycolic acids (MAs) are the characteristic, integral building blocks for the mycomembrane belonging to the insidious bacterial pathogen Mycobacterium tuberculosis (M.tb). These C60-C90 long α-alkyl-β-hydroxylated fatty acids provide protection to the tubercle bacilli against the outside threats, thus allowing its survival, virulence and resistance to the current antibacterial agents. In the post-genomic era, progress has been made towards understanding the crucial enzymatic machineries involved in the biosynthesis of MAs in M.tb. However, gaps still remain in the exact role of the phosphorylation and dephosphorylation of regulatory mechanisms within these systems. To date, a total of 11 serine-threonine protein kinases (STPKs) are found in M.tb. Most enzymes implicated in the MAs synthesis were found to be phosphorylated in vitro and/or in vivo. For instance, phosphorylation of KasA, KasB, mtFabH, InhA, MabA, and FadD32 downregulated their enzymatic activity, while phosphorylation of VirS increased its enzymatic activity. These observations suggest that the kinases and phosphatases system could play a role in M.tb adaptive responses and survival mechanisms in the human host. As the mycobacterial STPKs do not share a high sequence homology to the human's, there have been some early drug discovery efforts towards developing potent and selective inhibitors | ||
| 520 | |a OBJECTIVE: Recent updates to the kinases and phosphatases involved in the regulation of MAs biosynthesis will be presented in this mini-review, including their known small molecule inhibitors | ||
| 520 | |a CONCLUSION: Mycobacterial kinases and phosphatases involved in the MAs regulation may serve as a useful avenue for antitubercular therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Mycobacterium | |
| 650 | 4 | |a formulations | |
| 650 | 4 | |a kinase | |
| 650 | 4 | |a mycolic acids | |
| 650 | 4 | |a phosphatase | |
| 650 | 4 | |a small molecule inhibitors | |
| 650 | 4 | |a tuberculosis. | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Mycolic Acids |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Small Molecule Libraries |2 NLM | |
| 650 | 7 | |a Fatty Acid Synthases |2 NLM | |
| 650 | 7 | |a EC 2.3.1.85 |2 NLM | |
| 650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Protein Tyrosine Phosphatases |2 NLM | |
| 650 | 7 | |a EC 3.1.3.48 |2 NLM | |
| 700 | 1 | |a Beh, Chau C |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Neil R |e verfasserin |4 aut | |
| 700 | 1 | |a Payne, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Gunosewoyo, Hendra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d 2008 |g 12(2019), 1 vom: 25., Seite 27-49 |w (DE-627)NLM185149499 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2019 |g number:1 |g day:25 |g pages:27-49 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1874467211666181025141114 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2019 |e 1 |b 25 |h 27-49 | ||